Pages that link to "Q45256304"
Jump to navigation
Jump to search
The following pages link to Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy (Q45256304):
Displaying 50 items.
- Pregabalin add-on for drug-resistant partial epilepsy (Q24197972) (← links)
- Pregabalin add-on for drug-resistant partial epilepsy (Q24242802) (← links)
- Pregabalin modulation of neurotransmitter release is mediated by change in intrinsic activation/inactivation properties of ca(v)2.1 calcium channels (Q30498941) (← links)
- Rational Polytherapy with Antiepileptic Drugs (Q33664046) (← links)
- Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. (Q33735269) (← links)
- Modeling Longitudinal Daily Seizure Frequency Data From Pregabalin Add‐On Treatment (Q33925036) (← links)
- A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD) (Q34183517) (← links)
- Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials (Q34563933) (← links)
- Negative effects of antiepileptic drugs on mood in patients with epilepsy (Q34580773) (← links)
- Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. (Q34965263) (← links)
- Pregabalin in childhood epilepsy: a clinical trial study (Q35016781) (← links)
- The cognitive impact of antiepileptic drugs (Q35588407) (← links)
- Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy (Q35995395) (← links)
- Pregabalin: as adjunctive treatment of partial seizures (Q36058910) (← links)
- Defining success in clinical trials--profiling pregabalin, the newest AED. (Q36249983) (← links)
- Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis (Q36284727) (← links)
- Pregabalin: a new neuromodulator with broad therapeutic indications (Q36313119) (← links)
- A big data approach to the development of mixed-effects models for seizure count data. (Q36332317) (← links)
- Pregabalin: an antiepileptic agent useful for neuropathic pain (Q36873029) (← links)
- Weight issues for people with epilepsy--a review (Q37019215) (← links)
- Clinical perspectives on lacosamide (Q37156322) (← links)
- Pregabalin in the management of partial epilepsy (Q37318734) (← links)
- Extended-release formulations of antiepileptic drugs: rationale and comparative value (Q37423598) (← links)
- Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis (Q37594857) (← links)
- Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial. (Q37658349) (← links)
- Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last (Q37733552) (← links)
- A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin (Q37785529) (← links)
- Pharmacotherapy for children and adolescents with epilepsy (Q37826193) (← links)
- Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis (Q37832531) (← links)
- The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. (Q37841667) (← links)
- Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis (Q37975526) (← links)
- Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy (Q38064486) (← links)
- Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal (Q38076077) (← links)
- Weight change, genetics and antiepileptic drugs (Q38168942) (← links)
- The discovery and development of perampanel for the treatment of epilepsy (Q38190084) (← links)
- Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective (Q38199973) (← links)
- Drug-induced cerebellar ataxia: a systematic review (Q38267726) (← links)
- Participation of K(ATP) Channels in the Antinociceptive Effect of Pregabalin in Rat Formalin Test (Q38395914) (← links)
- Glossopharyngeal neuralgia responding to pregabalin (Q39346699) (← links)
- Investigation of influencing factors on higher placebo response in East Asian versus Western clinical trials for partial epilepsy: a meta-analysis (Q39445131) (← links)
- The opening effect of pregabalin on ATP-sensitive potassium channels in differentiated hippocampal neuron-derived H19-7 cells (Q40285342) (← links)
- Pregabalin: the next new thing (Q40578803) (← links)
- Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial (Q41161423) (← links)
- Epilepsy, antiseizure therapy, and sleep cycle parameters (Q42562997) (← links)
- Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials (Q42654256) (← links)
- Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies (Q42674848) (← links)
- Cost-effectiveness of pregabalin: a UK perspective. (Q43042808) (← links)
- Clinical pharmacokinetics of pregabalin in healthy volunteers (Q43165981) (← links)
- Pregabalin for the management of partial epilepsy (Q43176295) (← links)
- The impact of background antiepileptic drugs on the efficacy and safety of pregabalin in treating partial-onset seizures: A post hoc analysis of combined clinical trials (Q43559518) (← links)